GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Myos Rens Technology Inc (NAS:MYOS) » Definitions » Beneish M-Score

Myos Rens Technology (Myos Rens Technology) Beneish M-Score : 0.00 (As of Apr. 26, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Myos Rens Technology Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Myos Rens Technology's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Myos Rens Technology was 0.00. The lowest was 0.00. And the median was 0.00.


Myos Rens Technology Beneish M-Score Historical Data

The historical data trend for Myos Rens Technology's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myos Rens Technology Beneish M-Score Chart

Myos Rens Technology Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.84 -87.52 -3.18 21.57 -4.93

Myos Rens Technology Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.59 -4.93 -2.57 -2.35 -3.44

Competitive Comparison of Myos Rens Technology's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Myos Rens Technology's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myos Rens Technology's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Myos Rens Technology's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Myos Rens Technology's Beneish M-Score falls into.



Myos Rens Technology Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Myos Rens Technology for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7375+0.528 * 0.8707+0.404 * 0.7465+0.892 * 1.8491+0.115 * 1.041
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.5202+4.679 * -0.288022-0.327 * 1.135
=-3.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep20) TTM:Last Year (Sep19) TTM:
Total Receivables was $0.06 Mil.
Revenue was 0.485 + 0.329 + 0.29 + 0.379 = $1.48 Mil.
Gross Profit was 0.237 + 0.157 + 0.132 + 0.298 = $0.82 Mil.
Total Current Assets was $2.31 Mil.
Total Assets was $3.28 Mil.
Property, Plant and Equipment(Net PPE) was $0.23 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.30 Mil.
Selling, General, & Admin. Expense(SGA) was $4.43 Mil.
Total Current Liabilities was $0.85 Mil.
Long-Term Debt & Capital Lease Obligation was $0.41 Mil.
Net Income was -0.815 + -0.771 + -0.866 + -1.187 = $-3.64 Mil.
Non Operating Income was 0 + -0.007 + -0.013 + 0 = $-0.02 Mil.
Cash Flow from Operations was -0.543 + -0.724 + -0.944 + -0.463 = $-2.67 Mil.
Total Receivables was $0.04 Mil.
Revenue was 0.35 + 0.154 + 0.149 + 0.149 = $0.80 Mil.
Gross Profit was 0.176 + 0.073 + 0.088 + 0.051 = $0.39 Mil.
Total Current Assets was $2.16 Mil.
Total Assets was $3.57 Mil.
Property, Plant and Equipment(Net PPE) was $0.33 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.47 Mil.
Selling, General, & Admin. Expense(SGA) was $4.60 Mil.
Total Current Liabilities was $1.05 Mil.
Long-Term Debt & Capital Lease Obligation was $0.16 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.06 / 1.483) / (0.044 / 0.802)
=0.040459 / 0.054863
=0.7375

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.388 / 0.802) / (0.824 / 1.483)
=0.483791 / 0.55563
=0.8707

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2.313 + 0.229) / 3.281) / (1 - (2.163 + 0.332) / 3.573)
=0.225236 / 0.301707
=0.7465

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1.483 / 0.802
=1.8491

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.47 / (0.47 + 0.332)) / (0.295 / (0.295 + 0.229))
=0.586035 / 0.562977
=1.041

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(4.427 / 1.483) / (4.602 / 0.802)
=2.985165 / 5.738155
=0.5202

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.405 + 0.854) / 3.281) / ((0.16 + 1.048) / 3.573)
=0.383724 / 0.338091
=1.135

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-3.639 - -0.02 - -2.674) / 3.281
=-0.288022

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Myos Rens Technology has a M-score of -3.44 suggests that the company is unlikely to be a manipulator.


Myos Rens Technology Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Myos Rens Technology's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Myos Rens Technology (Myos Rens Technology) Business Description

Traded in Other Exchanges
N/A
Address
45 Horsehill Road, Suite 106, Cedar Knolls, NJ, USA, 07927
Myos Rens Technology Inc is a US-based bio-nutrition and biotherapeutics company. It focuses on the discovery, development, and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. The company develops nutritional and therapeutic products for maintaining and improving the health and performance of muscle tissue. Its research is focused on developing strategies and therapeutic interventions to address muscle related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases such as Sarcopenia, Cachexia, and others.
Executives
Joseph Mannello director, officer: Chief Executive Officer C/O BREAN CAPITAL, LLC, 1345 AVENUE OF THE AMERICAS, 29TH FLOOR, NEW YORK NY 10105
Victor E Mandel director PO BOX 5962, WASHINGTON DC 20016
Robert J Hariri director 341 MENDHAM ROAD, BERNARDSVILLE NJ 07924
Christopher Pechock director C/O MATLINPATTERSON GLOBAL ADVISORS INC, 520 MADISON AVE, NEW YORK NY 10022-4213
Christopher C Dewey director 120 BROADWAY, 27TH FLOOR, NEW YORK NY 10271
Louis J. Aronne director 4640 ADMIRALTY, SUITE 500, MARINA DEL RAY CA 90292
Eric Zaltas director 45 HORSEHILL ROAD SUITE 106, CEDAR KNOLLS NJ 07927
Andrew Joel Ponte director 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927
David J Matlin 10 percent owner
John Nosta director 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927
Zhengguang Lyu director 16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019
Ren Ren director, 10 percent owner 16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019
Rens Technology Inc 10 percent owner 150 DRAKE STREET ROOM 7F, POMONA CA 91767
Rens Agriculture Science & Technology Co, Ltd 10 percent owner 16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019
Guiying Zhao director 16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019

Myos Rens Technology (Myos Rens Technology) Headlines

From GuruFocus